Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer

  • Authors:
    • Lihong Zhang
    • Xuejing Yang
    • Zhen Sun
    • Jiali Li
    • Hui Zhu
    • Jing Li
    • Yan Pang
  • View Affiliations

  • Published online on: February 24, 2016     https://doi.org/10.3892/ol.2016.4273
  • Pages: 2605-2610
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate the survival time, immune response and safety of a dendritic cell (DC) vaccine and cytokine-induced killer (CIK) cell therapy (DC-CIK) in advanced non-small cell lung cancer (NSCLC). The present retrospective study enrolled 507 patients with advanced NSCLC; 99 patients received DC-CIK [immunotherapy group (group I)] and 408 matched patients did not receive DC-CIK, and acted as the control [non-immunotherapy group (group NI)]. Delayed-type hypersensitivity (DTH), quality of life (QOL) and safety were analyzed in group I. The follow‑up period for the two groups was 489.2±160.4 days. The overall survival (OS) time was calculated using the Kaplan‑Meier method. DTH was observed in 59 out of 97 evaluated patients (60.8%) and 67 out of 98 evaluated patients (68.4%) possessed an improved QOL. Fever and a skin rash occurred in 36 out of 98 patients (36.7%) and 7 out of 98 patients (7.1%) in group I. DTH occurred more frequently in patients with squamous cell carcinoma compared with patients with adenocarcinoma (77.1 vs. 40.4%; P=0.0013). Radiotherapy was not associated with DC‑CIK‑induced DTH (72.7 vs. 79.6%; P=0.18), but chemotherapy significantly reduced the rate of DTH (18.2 vs. 79.6%; P=0.00). The OS time was significantly increased in group I compared with group NI (P=0.03). In conclusion, DC-CIK may induce an immune response against NSCLC, improve the QOL, and prolong the OS time of patients, without adverse effects. Therefore, the present study recommends DC-CIK for the treatment of patients with advanced NSCLC.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 11 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang L, Yang X, Sun Z, Li J, Zhu H, Li J and Pang Y: Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. Oncol Lett 11: 2605-2610, 2016.
APA
Zhang, L., Yang, X., Sun, Z., Li, J., Zhu, H., Li, J., & Pang, Y. (2016). Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. Oncology Letters, 11, 2605-2610. https://doi.org/10.3892/ol.2016.4273
MLA
Zhang, L., Yang, X., Sun, Z., Li, J., Zhu, H., Li, J., Pang, Y."Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer". Oncology Letters 11.4 (2016): 2605-2610.
Chicago
Zhang, L., Yang, X., Sun, Z., Li, J., Zhu, H., Li, J., Pang, Y."Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer". Oncology Letters 11, no. 4 (2016): 2605-2610. https://doi.org/10.3892/ol.2016.4273